A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/395 (2006.01) A61P 37/06 (2006.01)
Patent
CA 2653387
A method of treating an autoimmune disease, such as, diabetes or psoriasis, by administering an anti-CD3 antibody, or anti-CD3 antibody fragment. The anti-CD3 antibody, or anti-CD3 antibody fragment, is administered over a course of treatment wherein, during the course of treatment, the anti-CD3 antibody, or anti-CD3 antibody fragment is administered in a total amount which does not exceed 300 µg/kg when administered intravenously or, when administered other than intravenously, is administered in a total amount that does not exceed a total amount bioequivalent to 300µg/kg of intravenous administration thereof.
La présente invention concerne un procédé de traitement d'une maladie auto-immune, telle que le diabète ou le psoriasis, par l'administration d'un anticorps anti-CD3, ou d'un fragment d'anticorps anti-CD3. L'anticorps anti-CD3, ou le fragment d'anticorps anti-CD3, est administré au cours d'un traitement durant lequel la quantité totale d'anticorps anti-CD3 ou de fragment d'anticorps anti-CD3 administrée n'excède pas 300 µg/kg dans le cas d'une injection intraveineuse. Dans le cas d'une administration autre que par injection intraveineuse, la quantité totale administrée n'excède pas une quantité totale bioéquivalente à l'injection intraveineuse de 300 µg/kg.
Ponath Paul
Rosenzweig Michael
Vaickus Louis
Smart & Biggar
Tolerrx Inc.
LandOfFree
Administration of anti-cd3 antibodies in the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Administration of anti-cd3 antibodies in the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Administration of anti-cd3 antibodies in the treatment of... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1413639